Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

FRONTIER4 data on investigational denecimig: Exploring efficacy and safety across dosing frequencies for pediatric, adolescent, and adult hemophilia A patients, with or without inhibitors Explorer10 data on concizumab (Alhemo®): Details presented for pediatric hemophilia A or B patients...